Sage Therapeutics, Inc. (SAGE)
收市後：
| 前收市價 | 6.99 |
| 開市 | 6.63 |
| 買盤 | 6.62 x 300 |
| 賣出價 | 6.67 x 100 |
| 今日波幅 | 6.47 - 7.04 |
| 52 週波幅 | 6.47 - 28.26 |
| 成交量 | |
| 平均成交量 | 748,534 |
| 市值 | 405.375百萬 |
| Beta 值 (5 年，每月) | 0.91 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -7.41 |
| 業績公佈日 | 2024年11月05日 - 2024年11月11日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 14.59 |
Insider MonkeySage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now
We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other Worst 52-Week Low Stocks. The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the […]
ZacksSAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.
BenzingaBiogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
On Thursday, Sage Therapeutics Inc. (NASDAQ:SAGE) announced that Biogen Inc (NASDAQ:BIIB) had terminated its rights under the collaboration and license agreement with Sage, which was specific to the SAGE-324 program. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET. Essential tremor is a neurological disorder that causes
